Fluzone Intradermal vaccine is indicated for active immunization of adults 18 through 64 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.
The vaccine, which features an ultra-fine needle that is 0.06 inches (1.5 mm) in length, contains 9 mcg of hemagglutinin per strain of influenza in a 0.1 mL dose.
The vaccine incorporates a prefilled microinjection system designed to deposit vaccine antigens into the dermal layer of the skin of adults.
The dermal layer contains a high concentration of specialized cells known as dendritic cells which play a key role in generating an immune response.
In clinical trials, Fluzone Intradermal vaccine produced an immune response at rates similar to Fluzone vaccine administered intramuscularly.